A Merck executive recently stated that its blockbuster cancer drug Keytruda is facing the impact of patent exclusivity expiration, which is more like a "gentle slope rather than a cliff" shock.
Show original
The executive predicts that after a brief period of slight sales decline, this blockbuster drug will soon return to a strong growth trajectory. This metaphor vividly illustrates Keytruda's development path after its patent protection expires. Contrary to the widespread concerns about the impact of biosimilars, Merck's management demonstrates confidence in product lifecycle management. They expect only a moderate sales pullback, followed by a recovery driven by market expansion and indication broadening. Industry analysis points out that as the world's best-selling PD-1 inhibitor, Keytruda's market position is difficult to fully replace in the short term. Even facing patent expiration, the drug's core role in treatment guidelines for multiple cancer types, as well as Merck's established and comprehensive market system, will provide strong support for its performance.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!
You may also like
Trending news
MoreShareholders of Blue Owl Capital Corporation (OBDC) who choose to participate in the tender offer initiated by Cox and Saba will receive a per-share consideration significantly lower than the current net asset value (NAV) of the investment company.
According to the latest disclosed information, shareholders of the OBDC II project under Blue Owl Capital are expected to receive significant cash returns in 2026.
Crypto prices
MoreBitcoin
BTC
$68,114.29
-4.15%
Ethereum
ETH
$1,983
-4.66%
Tether USDt
USDT
$0.9999
-0.01%
BNB
BNB
$630.83
-3.11%
XRP
XRP
$1.36
-3.77%
USDC
USDC
$1.0000
-0.00%
Solana
SOL
$85.36
-4.00%
TRON
TRX
$0.2850
+0.74%
Dogecoin
DOGE
$0.09075
-3.55%
Cardano
ADA
$0.2591
-3.97%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now